Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Breast Cancer Res Treat ; 83(1): 1-10, 2004 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-14997049

RESUMEN

Determining the risk that a particular area of hyperplastic breast tissue will progress to cancer is difficult and is currently expressed only as a general risk factor within the population. Using an antibody against the apoptotic purinergic receptor P2X7, we examined 40 cases each of the following histological categories: normal, moderate, florid and atypical hyperplasia, lobular carcinoma in situ, ductal carcinoma in situ, invasive lobular and invasive ductal carcinoma. These were previously diagnosed by H&E and supplied by clinical laboratories as tissue sections. Normal and mildly hyperplastic epithelium was devoid of the cytolytic P2X7 receptors whereas all epithelial cells in all cases of in situ or invasive lobular or ductal carcinoma labelled intensely. The lobular and ductal in situ cases labelled intracellularly while the invasive epithelial cancer cells showed intense cell surface label indicating an attempt was being made to induce apoptosis. All these receptors however are non-functional and thus unable to induce apoptosis. Approximately 10% of all hyperplastic lobules examined in the biopsied tissue, regardless of H&E classification, labelled for P2X7, which is suggestive of early metabolic cancerous change. The acini within lobules were either completely labelled with P2X7 or were completely devoid of the receptor. A potential advantage of this method lies in identifying early cancerous change in hyperplastic lobules and in establishing the true extent of cancerous spread in infiltrating lesions, thus facilitating the task of reporting clear surgical margins.


Asunto(s)
Neoplasias de la Mama/metabolismo , Mama/metabolismo , Lesiones Precancerosas/metabolismo , Receptores Purinérgicos P2/metabolismo , Mama/patología , Neoplasias de la Mama/patología , Carcinoma Ductal de Mama/metabolismo , Carcinoma Ductal de Mama/patología , Carcinoma Intraductal no Infiltrante/metabolismo , Carcinoma Intraductal no Infiltrante/patología , Carcinoma Lobular/metabolismo , Carcinoma Lobular/patología , Femenino , Enfermedad Fibroquística de la Mama/metabolismo , Enfermedad Fibroquística de la Mama/patología , Humanos , Inmunohistoquímica/métodos , Lesiones Precancerosas/patología , Valor Predictivo de las Pruebas , Receptores Purinérgicos P2X7
2.
Melanoma Res ; 13(2): 137-45, 2003 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-12690296

RESUMEN

Extensive labelling for the apoptotic markers calcium channel receptor P2X(7) and caspase-3 and telomerase activity was co-localized at a similar intensity in areas affected by superficial spreading melanoma obtained from 80 patients. Labelling for each of these markers also extended 2 microm from the melanoma into the keratinocyte layer of the adjacent normal epidermis. Conversely, the calcium-regulating receptors P2X(1-3) and P2Y(2) (found in normal but not neoplastic skin) were fully de-expressed within 2 microm of the melanoma but fully expressed beyond that distance. The cell adhesion protein E-cadherin (also only present in normal skin) was progressively de-expressed from a point 2 microm from the melanoma until full de-expression within the lesion. These results show that telomerase-induced proliferation and defensive apoptosis are co-localized and simultaneous processes in melanoma tissue. Melanoma cell proliferation appears to overwhelm the apoptotic defence, perhaps due to the anti-apoptotic effects of telomerase. In addition, keratinocyte regulation of the epidermis and dermis is severely compromised by the loss of E-cadherin and P2X(1-3) and P2Y(2) receptors, resulting in a lesion that is aggressive and malignant.


Asunto(s)
Apoptosis , Biomarcadores de Tumor/biosíntesis , Caspasas/biosíntesis , Melanoma/metabolismo , Melanoma/patología , Receptores Purinérgicos P2/biosíntesis , Telomerasa/biosíntesis , Cadherinas/biosíntesis , Cadherinas/metabolismo , Caspasa 3 , Adhesión Celular , División Celular , Núcleo Celular/metabolismo , Dermis/metabolismo , Precursores Enzimáticos/biosíntesis , Epidermis/metabolismo , Humanos , Inmunohistoquímica , Queratinocitos/metabolismo , Melanocitos/metabolismo , Receptores Purinérgicos P2X7 , Telomerasa/metabolismo , Factores de Tiempo
3.
J Pathol ; 199(3): 368-77, 2003 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-12579539

RESUMEN

Biochemical and genetic changes precede histologically identifiable changes accompanying cell transformation often by months or years. De-expression of the extracellular matrix adhesive glycoprotein tenascin and the cell-to-cell adherent protein E-cadherin have been suggested as markers of early neoplastic change in prostate epithelial cells. Previous studies have been inconclusive, probably due to epitope masking. This study examined 2,378 biopsy cores from 289 prostates using a heat antigen retrieval protocol at low pH to improve the accuracy of detection. Tenascin and E-cadherin de-expression was correlated with purinergic receptor and telomerase-associated protein labelling, as well as prostate-specific antigen (PSA) levels and Gleason scores. E-cadherin was a poor marker, as it was expressed in all lesions except carcinomas of the highest Gleason score. Tenascin was maximally expressed in the extracellular matrix and acinar basement membrane in normal and prostatic intraepithelial neoplasia tissue. In prostate cancer tissue, tenascin expression did not correlate with Gleason score but was significantly de-expressed as purinergic receptor and telomerase-associated protein expression increased. Marked changes in tenascin, telomerase-associated protein, and purinergic receptor expression were apparent before any histological abnormalities were visible by haematoxylin and eosin (H&E) stain, making these potential markers for early and developing prostate cancer. Moreover, the potential increased accuracy of diagnosis of underlying prostate cancer using purinergic receptor translocation (PRT) assessment suggests that PSA levels may be more accurate than has generally been supposed when apparent false negatives arising from H&E-based diagnoses are correctly categorized.


Asunto(s)
Biomarcadores de Tumor/análisis , Proteínas de Neoplasias/análisis , Lesiones Precancerosas/diagnóstico , Neoplasia Intraepitelial Prostática/diagnóstico , Neoplasias de la Próstata/diagnóstico , Anciano , Anciano de 80 o más Años , Cadherinas/análisis , Proteínas Portadoras/análisis , Humanos , Masculino , Persona de Mediana Edad , Lesiones Precancerosas/patología , Antígeno Prostático Específico/análisis , Neoplasia Intraepitelial Prostática/patología , Neoplasias de la Próstata/patología , Proteínas de Unión al ARN , Receptores Purinérgicos/análisis , Tenascina/análisis
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...